Diagnostic performance of bone scintigraphy and 11C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer

被引:15
|
作者
Garcia, J. R. [1 ]
Moreno, C. [1 ]
Valls, E. [1 ]
Cozar, P. [1 ]
Bassa, P. [1 ]
Soler, M. [1 ]
Alvarez-Moro, F. J. [1 ]
Moragas, M. [1 ]
Riera, E. [1 ]
机构
[1] Unidad PET CETIR ERESA, Barcelona, Spain
关键词
Bone scintigraphy; C-11-Choline PET/CT; Bone metastases; Biochemical recurrence; Prostate cancer; POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; F-18-FLUORIDE PET; F-18-FDG PET/CT; DISEASE; SPECT; ONCOLOGY; RELAPSE; CT;
D O I
10.1016/j.remn.2014.08.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: To compare bone scan (BS) with C-11-Choline PET/CT for the detection of bone metastases in patients with biochemical recurrence of prostate cancer (PC). Material and Methods: A total of 169 patients with biochemical recurrence of PC(PSA:2.4-58 ng/ml) who were referred for both exams (0-15 days-in-between) were included. Lesion-detection-rate per patients and lesions were analyzed for both BS and C-11-Choline PET/CT. Metastasis diagnosis was reached by: biopsy, CT/F-18-Fluoride PET/MRI confirmation, or evidence of progression in subsequent imaging procedures. Results: A total of 91 lesions were found to be active in BS and/or C-11-choline PET/CT (40 patients), with 78 of which were metastatic. BS detected 38 blastic, 2 lytic and 10 non-CT-evident lesions. C-11-Choline PET/CT detected 41 blastic, 4 lytic and 29 non-CT-evident lesions. BS and C-11-Choline PET/CT sensitivities were 65.4% and 96.1%; specificities ere 38.5 and 92.3% (chi(2) 8.27, p < 0.04). Both imaging techniques were negative in 118 patients. Tracer avid lesions were found in 51 patients: with 30/51 being BS and C-11-Choline PET/CT concordant; in 21/51 patients had discordant lesions (kappa 0.712, p = 0.00). Lesions were absolutely discordant in 10/19 patients,: 5 FN BS, 2 FP BS (degenerative changes: dysplasia), 1 FN C-11-Choline PET/CT (blastic), 1 FP C-11-Choline PET/CT (degenerative), 1 out of field-of-view lesion with C-11-Choline PET/CT (tibia alone). C-11-Choline PET/CT showed extraosseous involvement in 26/51 patients with bone metastases: 9 local recurrences, 5 infra-diaphragmatic-lymph-nodes, 2 supra-diaphragmatic, 5 local and infra-diaphragmatic, 4 infra- and supra-diaphragmatic, 1 supra-diaphragmatic and lung metastases. Conclusion: C-11-Choline PET/CT yielded better sensitivity and specificity than BS for the detection of bone involvement in patients with biochemical recurrence of PC and allowed extraosseous restaging, with an impact in the clinical management of these patients. (C) 2014 Elsevier Espana, S.L.U. and SEMNIM. All rights reserved.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 50 条
  • [21] A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer
    Wondergem, Maurits
    van der Zant, Friso M.
    van der Ploeg, Tjeerd
    Knol, Remco J. J.
    NUCLEAR MEDICINE COMMUNICATIONS, 2013, 34 (10) : 935 - 945
  • [22] Comparison of [11C]Choline PET/CT and bone scintigraphy in the detection of bone metastasis in patients with biochemical failure after primary treatment for prostate cancer
    Picchio, M.
    Fallanca, F.
    Spinapolice, E.
    Crivellaro, C.
    Oliveira, P.
    Landoni, C.
    Gianolli, L.
    Messa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S269 - S269
  • [23] Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence
    Spick, Claudio
    Polanec, Stephan H.
    Mitterhauser, Markus
    Wadsak, Wolfgang
    Anner, Philip
    Reiterits, Bettina
    Haug, Alexander R.
    Hacker, Marcus
    Beheshti, Mohsen
    Karanikas, Georgios
    ANTICANCER RESEARCH, 2015, 35 (12) : 6787 - 6791
  • [24] Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer
    Garcia, J. R.
    Ponce, A.
    Canales, M.
    Ayuso, J.
    Moragas, M.
    Soler, M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2014, 33 (01): : 28 - 31
  • [25] Performance diagnosis of 11c-choline pet/ct in prostate cancer
    Samper Ots, P. M.
    Luis Cardo, A.
    Cabeza Rodriguez, M. A.
    Vallejo Ocana, C.
    Glaria Enriquez, L. A.
    Couselo Paniagua, M. L.
    Olivera Vegas, J.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S709 - S709
  • [26] Clinical Indications of 11C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse
    Picchio, Maria
    Castellucci, Paolo
    THERANOSTICS, 2012, 2 (03): : 313 - 317
  • [27] 11C-choline PET/CT and bone lesions in recurrent prostate cancer patients with fast PSA kinetics
    Ceci, F.
    Castellucci, P.
    Graziani, T.
    Schiavina, R.
    Morigi, J. J.
    Bonfiglioli, R.
    Sanfilippo, S.
    Beeresova, M.
    Costa, S.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S213 - S214
  • [28] 11C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer
    Garcia, J. R.
    Romera, N.
    Cozar, M.
    Soler, M.
    Moragas, M.
    Escobar, M.
    ACTAS UROLOGICAS ESPANOLAS, 2015, 39 (04): : 259 - 263
  • [29] How much CT do we need in 11C-Choline PET/CT in patients suffering from prostate cancer with suspicion of bone metastases?
    Tuncel, M.
    Souvatzoglou, M.
    Herrman, K.
    Stollfuss, J.
    Schwaiger, M.
    Krause, B. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S208 - S208
  • [30] Sequential PET/CT with 11C-Choline in Monitoring Treatment Response to Androgen Deprivation in Patients with Biochemical Recurrence of Prostate Cancer
    Medina-Quiroz, P.
    Quirce, R.
    Banzo, I.
    De Arcocha-Torres, M.
    Rubio-Vassallo, A.
    Ortega-Nava, F.
    Gutierrez-Banos, F.
    Campos-Juanatey, F.
    Acuna, E.
    Carril, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S574 - S575